Aktis Oncology, a Boston-based biotech company, plans to raise up to $212 million through an IPO on the Nasdaq under the ticker AKTS.[1][2] The firm filed with the Securities and Exchange Commission (SEC) to sell 11.8 million shares at a price of $16 to $18 per share.[1][3] At the upper price limit, it would reach a market value of approximately $840 million.[1] He will use the obtained funds for clinical trials of his advanced candidates for radiopharmaceuticals against solid tumors.[1][4] Founded in 2020/2021, the company specializes in targeted therapies with alpha-emitting radioactive substances.[1][3] It raised about $346 million from investors, including MPM (26%), Vida Ventures (14%) and EcoR1 Capital (11%), before its IPO.[1] In the nine months to September 30, it reported a loss of $48.6 million on revenue of $4.6 million, compared with a loss of $31.9 million on revenue of $554,000 in the same period a year ago.[1][2] It is currently conducting a phase 1b clinical trial for its lead candidate Ac-AKY-1189.[2]